Stock Markets March 9, 2026

XPeng Shares Edge Higher After Morgan Stanley Praises VLA 2.0 Test Ride

Analysts call Guangzhou demo 'impressive' as the autonomous update sparks buying interest amid wider market dip-buying

By Sofia Navarro XPEV
XPeng Shares Edge Higher After Morgan Stanley Praises VLA 2.0 Test Ride
XPEV

XPeng (NYSE:XPEV) stock rose after Morgan Stanley analysts reported favorable impressions from a hands-on 28-kilometer test of the automaker's VLA 2.0 autonomous driving system in Guangzhou. The brokerage highlighted smoother, more human-like control and said the immediate challenge is converting improved AD tech into broader consumer adoption and vehicle sales.

Key Points

  • Morgan Stanley analysts completed a 28-kilometer test ride of XPeng's VLA 2.0 in Guangzhou and described the experience as "impressive" with smoother, more human-like control.
  • The VLA 2.0 demonstration coincided with intraday buying - the stock rose as much as 6% earlier while the Hang Seng fell about 1% - with southbound inflows and some short covering cited as contributors.
  • XPeng faces the next challenge of converting improved AD tech recognition into wider consumer adoption and vehicle purchases; shares are down 14% year-to-date.

Shares of XPeng (NYSE:XPEV) climbed 2.6% following remarks from Morgan Stanley analysts who participated in a demonstration of the automaker's VLA 2.0 autonomous driving system in Guangzhou.

Morgan Stanley attended XPeng's VLA 2.0 workshop and completed a 28-kilometer test ride through Guangzhou's downtown Tianhe District after the company rolled out the update last week. In their assessment, the analysts said the on-road experience was notably improved.

"Today's test ride was impressive, with notably smooth and more human-like control," the Morgan Stanley analysts wrote.

The analysts added that, with the technical footing for advanced driver assistance (AD) now in place, the subsequent priority will be securing wider consumer recognition and turning that recognition into actual vehicle purchases. They emphasized that technology validation is only one step in achieving commercial traction.

Earlier in the trading day the stock had shown larger intraday movement, at one point rising about 6% compared with a roughly 1% decline in the Hang Seng Index. Morgan Stanley attributed the surge in part to the VLA 2.0 test ride, noting that the event appeared to spur southbound inflows and contributed to some short covering.

"More broadly, the market appears inclined to bottom-fish auto names, and XPeng's VLA 2.0 event provides a near-term catalyst for dip-buying," the analysts added.

Despite the intraday gains, XPeng shares remain lower year-to-date, down 14%.


Key takeaways

  • Positive in-person feedback from Morgan Stanley on XPeng's VLA 2.0 test ride helped lift the stock.
  • Market reaction included southbound inflows and short covering, and broader investor interest in buying dips among auto names.
  • Sectors impacted include electric vehicle manufacturers and broader equity markets where momentum trading and cross-border flows can influence price moves.

Risks and uncertainties

  • Technical validation does not guarantee consumer adoption - the analysts specified that converting recognition into vehicle purchases is the next crucial step.
  • Share price remains volatile - the stock experienced an intraday swing and is still down 14% year-to-date, reflecting ongoing market sensitivity.
  • Near-term gains may be driven by short covering and dip-buying rather than sustained fundamental improvement.

Risks

  • Improved AD technology does not automatically translate into higher vehicle sales - broader consumer recognition and purchase conversion remain necessary.
  • Price volatility from short covering and dip-buying can produce temporary gains that may not reflect sustained fundamentals.
  • XPeng's shares remain down 14% year-to-date, indicating market sensitivity and potential downside if consumer uptake lag persists.

More from Stock Markets

WuXi AppTec Shares Surge as Annual Profit More Than Doubles Mar 24, 2026 U.S. Stocks Showing Relative Resilience Amid Iran Conflict, but Risks Remain Mar 24, 2026 European New Car Registrations Tick Up in February as EV Momentum Continues Mar 24, 2026 Keymed Biosciences Set to Receive Up to $320 Million After Gilead Acquires Ouro Medicines Mar 24, 2026 Iran Fires Multiple Missile Waves at Israel as Negotiation Claims Are Disputed Mar 24, 2026